TNP-351

Cat. No.: CAS No.: Molecular Formula: Molecular Weight: Target: Pathway:	HY-19095 125991-51-7 C ₂₁ H ₂₄ N ₆ O ₅ 440.45 Antifolate Cell Cycle/DNA Damage	H_2N , N , H_2 N , H_N , H_2 H_N , H_N , H_2 , H_1 , H_2 ,
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.	

Product Data Sheet

BIOLOGICAL ACTIVITY Description TNP-351 is an antifolate. TNP-351, a dihydrofolate reductase (DHFR) inhibitor, has potent antitumor activity against not only leukemia cells but also solid tumor cells in vitro and in vivo^[1]. IC₅₀ & Target Antifolate, DHFR^[1] In Vitro TNP-351 inhibits the proliferation of mouse L1210 leukemia cells and human CCRF-CEM lymphoblastic leukemia cells with ED₅₀ values of 0.79 and 2.7 nM, respectively^[1]. The ED₅₀ values determined for the parent cell line CCRF-CEM, CCRFCEM R30/6 subline, CCRF-CEM R1, and CCRF-CEM R2 are 2.7, 5.8, 94 and 76 nM, respectively^[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Cell Viability Assay^[1] Cell Line: L1210 and CCRF-CEM cells Concentration: 0.1, 0.3, 1, 3, and 10 nM for L1210 cells; 0.3, 1, 3, 10, and 30 for CCRF-CEM cells Incubation Time: 48 hours for L1210 cells; 72 hours for CCRF-CEM cells Result: The ED₅₀ values were 0.79 and 2.7 nM for L1210 and CCRF-CEM cells, respectively.

REFERENCES

[1]. F Itoh, et al. Novel pyrrolo[2,3-d]pyrimidine Antifolate TNP-351: Cytotoxic Effect on Methotrexate-Resistant CCRF-CEM Cells and Inhibition of Transformylases of De Novo Purine Biosynthesis. Cancer Chemother Pharmacol. 1994;34(4):273-9.

Caution: Product has not been fully validated for medical applications. For research use only.

 Tel: 609-228-6898
 Fax: 609-228-5909
 E-mail: tech@MedChemExpress.com

 Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA